Navigation Links
CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
Date:3/3/2008

VIENNA, Va., March 3 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) provided details today at its 2008 Annual Meeting of Shareholders on groundbreaking activities currently underway at its manufacturing facility near Baltimore, Maryland. The facility will be used to manufacture Multikine(R), the Company's lead compound, for a pivotal Phase III clinical trial as first-line therapy of previously untreated head and neck cancer patients. The facility, which is being built by the design builder BE&K (http://www.bek.com/index.asp), is expected to be completed during the third quarter of 2008, with manufacturing and patient enrollment to begin soon thereafter.

"I am excited to announce to our shareholders the excellent progress we have made in constructing our manufacturing facility in the short period of time since we have broken ground," said Geert Kersten, CEL-SCI's Chief Executive Officer. "We believe the facility will provide us with tight control over the manufacturing process, eliminating a key risk of the pivotal trial. Multikine represents a completely novel medicine with blockbuster potential to treat a large unmet medical need and we are eager to begin this open label trial."

Mr. Kersten continued, "We are starting to receive more recognition for our work. The February 2008 issue of MedAdNews, a highly respected and authoritative publication serving the pharmaceutical industry, ran its 8th annual report on FUTURE BLOCKBUSTERS stating that 'These medicines are expected to eventually garner FDA approval and break the annual billion-dollar sales barrier'. Our Multikine was one of the 10 medicines named."

The article can be accessed on CEL-SCI's website at http://www.cel-sci.com under recent media coverage.

At the Annual Shareholder's Meeting, the Company's executives also provided highlights from fiscal year 2007. Some of the highlights include:

-- FDA clearance of Multikine for Phase III clinical trial in head and

neck cancer

-- Raised U.S. $15 million

-- Multikine granted Orphan drug designation in U.S.

-- Started build-out of manufacturing facility for Multikine to support

upcoming Phase III study and future commercial sale

-- Started planning and pricing of global clinical trial designed to lead

to marketing approval for Multikine

All matters submitted to a vote of the shareholders were approved by a vote of the shareholders at the Annual Meeting.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2007. The Company undertakes no obligation to publicly release the result of any revision to these forward- looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE CEL-SCI CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
3. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
4. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
5. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
6. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
7. Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date
8. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
9. National Atlantic Holdings Corporation to Report Fourth Quarter and Year-End 2007 Earnings on March 17, 2008
10. Linkwell Corporations Skin Disinfectant Product Chosen for 2008 Beijing Olympic Games
11. Partners Center for Connected Health and EMC Corporation Launch New Web-Based Remote Monitoring Program to Help Employees Fight Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... , ... January 14, 2017 , ... Wondering where to ... Dinner delivered straight to your door for a romantic, lobster feast in the comfort ... time for Valentine's Day. The dinners will be featured until February 15th, 2017. ...
(Date:1/14/2017)... Minneapolis, MN (PRWEB) , ... January 14, 2017 ... ... to present the distinctions among their expanding line of activated charcoal products. With ... emphasizes the importance of categorizing their products according to how they cater to ...
(Date:1/14/2017)... ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... frame transition from one clip to the next. , To use “Cut-Out First” ...
(Date:1/13/2017)... ... 2017 , ... A January 10 article in the Daily Star ... publication, with an emphasis on some new techniques that the publication says are becoming ... more casually to his patients and colleagues as Dr. J, comments that the best ...
(Date:1/13/2017)... ... ... An inventor from Pahrump, Nev., used an unsavory medical experience to think of a way ... and urine bag for a half year due to lazy bladder," he said. "Keeping these ... a better way to do this." , He then designed and created a prototype of ...
Breaking Medicine News(10 mins):
(Date:1/15/2017)... , January 16, 2017 Der ... Kollagenprodukten für die Regeneration des menschlichen Gewebes, gibt die ... mit sofortiger Wirkung bekannt. ... Bill Allan ... Er bekleidete eine Reihe von Geschäftsführer- und anderen Führungspositionen ...
(Date:1/13/2017)... Eli Lilly and Company (NYSE: ... ) announced today that the U.S. Food and Drug ... new drug application (NDA) for investigational baricitinib, a once-daily ... rheumatoid arthritis (RA). The NDA for baricitinib was submitted ... FDA extended the action date to allow time to ...
(Date:1/13/2017)... , Jan. 13, 2017 Wichita Laser ... cutting-edge laser treatments to Wichita, Kansas ... provides advanced treatments for skin rejuvenation, getting rid of ... lesions and vascular lesions. "Since being in ... in Wichita for laser tattoo ...
Breaking Medicine Technology: